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ABSTRACT
Correlation of Age-Specific Phenylalanine Levels on Intellectual Outcome in Patients
with Phenylketonuria
by
Krista S. Viau, Master of Science
Utah State University, 2010
Major Professor: Dr. Heidi Wengreen
Department: Nutrition, Dietetics, and Food Sciences
This study includes data collected from a retrospective chart review of patients
with phenylketonuria treated at the University of Utah Metabolic Clinic. Among the
approximately 175 patients treated for phenylketonuria at this clinic, 55 patients (28
female) met the inclusion criteria for the present study. Based on the diagnostic Phe
level, 66.7% were classified as having classic phenylketonuria, 18.5% with moderate
phenylketonuria, and 14.8% with mild phenylketonuria.
Subjects’ cognitive status was measured with one of three neuropsychological
tests: Wechsler Intelligence Scale for Children third and fourth editions and the
Wechsler Adult Intelligence Scale third edition. Due to structural differences among the
tests, only the Verbal Comprehension Index, Block Design subtest, and Symbol Search
subtest were compiled and included for statistical analysis.
Quality of metabolic control was assessed with blood and plasma phenylalanine
levels throughout each patient’s life. Three developmental age periods were defined (0-5
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years, 6-10 years, and >10 years). The index of dietary control (IDC), defined as mean of
median phenylalanine levels for each patient in 12-month intervals, was calculated for
each developmental period. The mean standard deviation (SD) of blood phenylalanine
levels and mean number of blood phenylalanine samples were also assessed in 12-month
intervals.
Linear regression analysis was used to evaluate the most recent measures of
intelligence in relationship to IDC and mean SD blood phenylalanine levels during
developmental periods. Logistic regression was also used to examine the association
between mean number of phenylalanine samples during each developmental period and
the likelihood of maintaining blood phenylalanine less than 360 μmol/L and within one
SD of the IDC.
Using multivariate linear regression, a model including IDC and number of
samples from lifetime, 0-5 years, and 6-10 years were significantly associated with
perceptual reasoning, but IDC regression coefficients were not significantly correlated.
Multivariate logistic regression revealed a 32 percent decrease in risk of IDC exceeding
the upper limit of the treatment range for each additional phenylalanine assessment per
year between the ages of 6-10 years (p = 0.001). No association was observed between
SD blood phenylalanine and cognitive outcomes or frequency of sampling during any
developmental periods.
(81 pages)
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CHAPTER 1
BACKGROUND AND INTRODUCTION
ABSTRACT
Phenylketonuria (PKU) is an inherited disorder of protein metabolism impairing
the body’s ability to metabolize the essential amino acid phenylalanine (Phe). It is
caused by a defect in the gene encoding phenylalanine hydroxylase (PAH) or defective
synthesis/recycling of the cofactor tetrahydrobiopterin (BH4). PKU is generally
diagnosed at birth through the Newborn Screening Program to facilitate prompt
treatment. If left untreated, it will result in severely impaired cognitive development. In
addition, pregnancy in women with PKU is challenging as elevated blood Phe is
extremely teratogenic. The primary treatment for PKU is strict control of dietary Phe
intake to the minimum amount needed to support growth and protein turnover. Patients
with PKU are advised to maintain this diet throughout life for optimal outcomes, but
adherence to the diet is arduous. Despite adequate treatment, patients with PKU may
demonstrate mild intellectual deficits in arithmetic, reading, basic spelling, and
perceptual skill that worsen over time. Multiple studies also revealed a significant
negative relationship between blood Phe concentration and intelligence quotient (IQ).
The primary objective of this study is to determine if there are certain developmental
periods in which phenylalanine levels have a greater impact on most recent measures of
intelligence. It will also examine the relationship between frequency of testing blood Phe
via filter paper cards and maintenance of Phe levels within the treatment range of 120 to
360 μmol/L.
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BACKGROUND
Phenylketonuria Defined
Phenylketonuria (PKU) is an autosomal recessive disorder of protein metabolism,
which inhibits the body’s ability to metabolize the essential amino acid phenylalanine
(Phe). Due to the deficiency or lack of the hepatic enzyme phenylalanine hydroxylase
(PAH) or its cofactor tetrahydrobiopterin (BH4), phenylalanine cannot be converted to the
amino acid tyrosine (Tyr). This results in the accumulation of Phe and a deficiency of
Tyr, a precursor to the neurotransmitters dopamine and norepinephrine in the central
nervous system (Waisbren et al. 2007).
PKU results in irreversible and progressive brain damage if left untreated.
Elevated Phe interferes with myelination, synaptic sprouting, and dendritic pruning of
cerebral tissue (Schulze et al. 2009). The brain is the most susceptible to the neurotoxic
effects of elevated Phe during the first years of life (Feldmann et al. 2005).

When PKU

is diagnosed during the neonatal period by newborn screening and managed by life-long
nutrition support, mental retardation and major neurological complications, including
seizures and spasticity, are prevented (Weglage et al. 1997).
PKU is the most common inborn error of metabolism. The highest rates of PKU are
seen in Ireland (1:4500) and Eastern Europe (Estonia: 1:6000, Hungary 1:9000, and Latvia
1:8700). Incidence in North America is approximately 1:10,000 live births (Waisbren et al.
2007). PKU is classified into three categories based on severity at diagnosis: classic PKU
(plasma Phe >1200 μmol/L), moderate PKU (plasma Phe 600-1200 μmol/L), or mild PKU
(plasma Phe 120-600 μmol/L) (Waisbren et al. 2007). Approximately 50 percent of detected
cases are classical PKU, 30 percent are moderate PKU, and 20 percent are mild (Schulze et
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al. 2009). Only two percent of individuals with hyperphenylalanemia have a defect in BH4
synthesis or recycling rather than a mutation in the PAH gene (Williams et al. 2008).
The inability to synthesize or regenerate the PAH cofactor BH4 results in one of
five different genetic conditions that mimic PKU with elevated phenylalanine levels.
These conditions were differentiated from PKU in the 1970s after it became clear that a
portion of patients with hyperphenylalanemia experienced neurological damage despite
early treatment. Administration of synthetic BH4 rapidly normalizes plasma Phe levels
without use of a Phe-restricted diet (Longo 2009).
Expanded Newborn Screening and
Diagnosis of PKU
The advent of newborn screening came about with the work of Asbjorn Folling in
Norway nearly 70 years ago (Brin et al. 2006). It was developed to identify disorders of
amino acid metabolism, which were not typically diagnosed until developmental delay or
other neurological symptoms became apparent (Schulze et al. 2009). State newborn
screening programs in the United States began approximately 40 years ago for PKU with
the filter paper-based testing technology developed by Robert Guthrie (Brin et al. 2006;
Longo 2009). This method involves placing capillary blood from a heel prick on an Agar
plate containing Bacillus subtilis, which requires Phe to grow. A Phe analog that inhibits
bacterial growth is also applied. High levels of phenylalanine counteract the inhibitor
and permit bacterial growth (Guthrie and Susi 1963; Schulze et al. 2009). This method
allows mass screening for PKU, as it is simple, inexpensive, reproducible, and accurate
(Blumenfeld et al. 1966).
Tandem mass spectrometry (MS/MS) was introduced to the newborn screening
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program in the late 1990s. MS/MS can simultaneously perform amino acid and
acylcarnitine analyses on the same blood sample, thus drastically increasing the number
of disorders included in the screening (Schulze et al. 2009). In order for a disease to be
included in the newborn screen, it must meet the following qualifications:
1. Condition is identifiable in a presymptomatic or early stage of the disease.
2. A test with the appropriate specificity and sensitivity is available for large
populations.
3. The benefits of early intervention were demonstrated (Schulze et al. 2009).
In January of 2006, the Utah Department of Health expanded its newborn
screening program from 4 disorders to 36 disorders, including diseases of amino acid,
fatty acid, and organic acid metabolism. The screening is done via blood sample
collected between 48 hours and 5 days after birth (Utah Administrative Code 2009). The
second specimen is collected between 7 to 28 days of age. According to Title 26 of the
Utah Health Code, all infants are tested, “except in the case where parents object on the
grounds that they are members of a specified, well-recognized religious organization
whose teachings are contrary to the tests required” (Utah Code 1998).
In addition to newborn screening in those infants who screen positive for PKU, a
urinary pterin test and dihydropterindine reductase (DHPR) blood spot test are customary
to differentiate between PKU and a disorder of BH4 synthesis or recycling, as the
treatment differs (Schulze et al. 2009).
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Etiology of PKU
PKU is characterized by a defect in the gene encoding the enzyme phenylalanine
hydroxylase (PAH) located on chromosome 12q22-24.1. Over 500 mutations in the PAH
gene have been identified and most patients have two different mutations (compound
heterozygotes) (Santos et al. 2010). This defect inhibits the stereospecific hydroxylation
of Phe, the committed step in the metabolism of this essential amino acid (Waisbren et al.
2007; Williams et al. 2008). The hydroxylation of Phe to Tyr requires PAH, the cofactor
BH4, molecular oxygen, and the enzymes responsible for regenerating BH4. While this
system is required for the conversion of Phe to Tyr, it is not needed for decarboxylation
or transamination reactions (see Figure 1-1). These alternate pathways produce the Phe
metabolites phenylpyruvate, phenylacetylglutamate, phenyl-lactate, and ohydroxyphenylacetate (Williams et al. 2008).

Figure 1-1 Phenylalanine metabolism (Williams et al. 2008)
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Hyperphenylalanemia caused by a defect in BH4 synthesis/recycling can result
from mutations in the gene encoding 6-pyruvoyl-tetrahydrobiopterin synthase (PTPS)
(60%), DHPR (30%), GTP cyclohydrolase I (5%) and pterin-4a-carbinolamine
dehydratase (PCD) (5%). The biosynthesis of BH4 in humans involves the catalyst GTP
cyclohydrolase I, which is required for the rate-limiting reaction. The enzyme activity is
regulated by GTP cyclohydrolase I feedback regulatory protein (GFRP) where it is
stimulated in the presence of increased Phe levels and inhibited with excess BH4. PTPS
converts 7,8-dihydroneopterin triphosphate to 6-pyruvoyl-tetrahydrobiopterin.
Sepiapterin reductase (SR) then catalyzes the two-step reaction to complete the synthesis
of BH4. Tetrahydrobiopterin donates electrons during the hydroxylation of Phe, Tyr, and
tryptophan. Lastly, the two enzymes PCD and DHPR are required to regenerate BH4
from its oxidized form (Longo 2009).
Phe homeostasis is regulated by dynamic input and runout flux. The primary
sources of Phe are dietary intake and endogenous regeneration of amino acid stores
(Williams et al. 2008). Utilization of Phe occurs when Phe is used to make proteins or
converted to Tyr or other metabolites. If the runout flux is continually disordered as it is
in PKU, the steady state concentrations will eventually change, resulting in an
accumulation of Phe and Phe metabolites (Williams et al. 2008).
The phenotypic outcome of PKU is multifactorial in origin as there are numerous
factors that influence the flux of Phe in humans, including variations in intestinal
absorption, hepatic uptake of dietary Phe, rate of protein synthesis, and influx of Phe
across the blood brain barrier (BBB) (Santos et al. 2010). Due to the heterogeneity in the
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PAH enzyme locus and individual differences, the phenotype-genotype correlation varies
considerably.
Maternal PKU
Elevated blood phenylalanine concentrations are teratogenic to the offspring of
women with PKU (Williams et al. 2008; Maillot et al. 2008). Specifically, high Phe can
lead to an increased rate of miscarriage, facial dysmorphism, mental retardation,
microcephaly, congenital heart disease, and intrauterine growth failure (Acosta and
Yannicelli 2001; Williams et al. 2008). Many of the birth defects associated with
maternal PKU syndrome are preventable with appropriate control of Phe concentrations
prior to conception and during pregnancy (Maillot et al. 2008). Fetal exposure to
maternal Phe levels is exacerbated by the transplacental gradient for Phe, which produces
ratios of 1:1.5 and up to 1:2.9 early in pregnancy (Williams et al. 2008). Therefore,
frequent monitoring and stringent control of phenylalanine levels are crucial during
pregnancy. Weekly Phe levels are recommended with a goal of Phe concentrations
between 100 to 250 μmol/L. Stability of Phe concentrations are also of importance, as
negative outcomes were observed in those with a large standard deviation even with
mean Phe concentrations within the treatment range (Maillot et al. 2008).
Dietary Treatment
The primary treatment for PKU is strict control of dietary Phe intake. If one only
consumed natural protein foods, the degree of protein restriction necessary to reduce
plasma Phe concentrations to treatment levels would lead to marked protein malnutrition,
failure-to-thrive, and death. Therefore, individuals with PKU must also supplement their
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diet with a phenylalanine-free medical formula that provides tyrosine and other amino
acids. Medical foods meet approximately 85 to 90 percent of the individual’s protein
needs (Przyrembel and Bremer 2000; Acosta and Yannicelli 2001). The University of
Utah Metabolic Clinic advises its patients with PKU to continue this diet throughout life
for optimal outcomes. The clinicians recommend maintaining Phe levels between 120
and 360 μmol/L.
Barriers to Compliance
Adherence to the prescribed diet for PKU is difficult and time-consuming.
Barriers include: the restrictive and often unpalatable diet, expense of medical food and
low protein food, difficulty taking prescribed medical foods at school or work, frequency
of testing, psychosocial issues, lack of health insurance, complicated diet planning, and
misunderstanding of the diet (Bilginsoy et al. 2005; Bik-Multanowski et al. 2009).
Qualitative interviews were conducted in New Zealand with 8 early-treated adults
concerning their experiences living with PKU. Most participants reported a “difference”
between oneself and peers in relation to eating patterns, often leading to lack of social
acceptance and exclusion. On the other hand, refusal of food also provoked anxiety, as
food is a common symbol of community and relationship. Participants described a
greater inclination to eat outside their diet prescription if the comfort and feelings of
others were at stake. Lastly, participants explained the difficulty coping with modern
responsibilities without the use of convenient food options (Frank et al. 2007).
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Prognosis for Early Treated Patients
Early therapy prevents mental retardation in patients with PKU; however, several
studies revealed intellectual deficits in patients with early and continuously treated PKU
(Weglage et al. 1997). Despite adequate treatment, PKU patients tend to demonstrate
mild deficits in arithmetic, reading comprehension, basic spelling and perceptual skill
that worsen over time (Chang et al. 2000). It has also been demonstrated that patients
with Phe levels above 400 μmol/L at time of testing perform poorly on executive function
tests (Stemerdink et al. 2000).
A significant negative association between Phe concentration and intelligence
quotient (IQ) was documented in a meta analysis (Waisbren et al. 2007). Regression
analyses showed a decrease in IQ of 1.3 to 3.9 points for every 100 μmol/L increase in
lifetime plasma Phe in early treated patients. Concurrent Phe levels (phenylalanine levels
at the time testing was performed) reduced the measured IQ by 0.5 to 1.4 points for every
100 μmol/L increase in plasma Phe (Waisbren et al. 2007). The stability of Phe
concentrations may also impact IQ. Anastasoaie et al. (2008) discovered a correlation
between the standard deviation of plasma Phe levels and the most recent measure of IQ.
Mean plasma Phe and mean standard deviation of plasma Phe achieved a statistically
significant positive correlation (r = 0.51, p = 0.004), indicating that those with higher
plasma Phe experienced more instability in Phe levels (Anastasoaie et al. 2008).
RESEARCH QUESTIONS
1. Are there certain developmental periods in which adequate control of plasma
Phe has a stronger influence on measures of intelligence?

10
2. Does frequency of blood levels positively correlate with the stability and
maintenance of plasma Phe within the treatment range?
OBJECTIVES
1. Objective 1: Analyze the index of dietary control (mean 12-month median Phe
levels) and mean standard deviation of Phe levels submitted via filter paper cards
and blood draws and analyzed by MS/MS during specific developmental periods
(0-5 years, 6-10 years, and >10 years) and compare them to the most recent
measures of IQ.
2. Objective 2: Examine the correlation between frequency of testing via filter
paper and plasma amino acids and maintenance of Phe levels within the
treatment range of 120 to 360 μmol/L and within one standard deviation of the
index of dietary control.
UNIVERSITY OF UTAH METABOLIC CLINIC
Adherence to dietary recommendations and recommended frequency of blood Phe
testing tends to decline after early childhood in patients followed by the University of
Utah Metabolic Clinic. This is of particular concern as brain development continues into
adolescence, thus increasing the risk for cognitive deficits later in life. Defining the
importance of metabolic control during specific developmental periods may improve
adherence to dietary treatment. In addition, demonstrating a link between frequency of
testing and metabolic control may encourage patients to send blood Phe samples as per
clinic recommendations.
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CONCLUSION
While the most deleterious effects of PKU can be prevented with prompt and
continuous dietary therapy, mild deficits in intelligence, academic achievement, and
executive function skills may still occur with appropriate treatment. The current
recommendation in the United States is to continue a Phe-restricted diet for life.
However, adherence to diet prescription typically begins to wane after early childhood.
This study aims to investigate the impact of appropriate control on neuropsychological
assessments during certain developmental periods to determine if there is a period where
strict dietary control is more pertinent than others. Evaluation of the association between
frequency of blood levels and control of Phe will help determine the next step in
improving self-monitoring.
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CHAPTER 2
LITERATURE REVIEW OF THE CONSEQUENCES, PATHOPHYSIOLOGY
AND TREATMENT OF PHENYLKETONURIA
ABSTRACT
Phenylketonuria (PKU) is an autosomal recessive disorder of protein metabolism
with devastating neurological consequences. If left untreated it causes profound mental
retardation, microcephaly, and behavior disturbances. Early treatment in the neonatal
period with a phenylalanine (Phe)-restricted diet prevents brain damage. However, early
treated patients often exhibit mild deficits in executive and intellectual functioning,
specifically, attention, processing speed, language, perception and visual spatial abilities.
These impairments are attributed to defects in myelination, white matter abnormalities,
and dopamine depletion in the prefrontal cortex. The brain is most vulnerable to elevated
Phe during development, which continues from early embryogenesis through
adolescence. Therefore, clinicians promote continuing a Phe-restricted diet throughout
life to achieve optimal outcomes. The diet consists of Phe-free amino acid modules and
measured amounts of natural protein to maintain blood Phe levels within a therapeutic
range. However, there is no consensus on the appropriate blood Phe concentrations for
this population. Additional treatment options for PKU are available, such as sapropterin
dihydrochloride (pharmacological equivalent of tetrahydrobiopterin), enzyme
replacement therapy, and large neutral amino acids.
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INTRODUCTION
Phenylketonuria (PKU) is an inherited disorder of protein metabolism, which
inhibits the body’s ability to metabolize the essential amino acid phenylalanine (Phe)
(Burgard et al. 2009). It is caused by a defect in the enzyme phenylalanine hydroxylase
(PAH) or by defective synthesis/recycling of its co-factor tetrahydrobiopterin (BH4).
Up to 90 percent of phenylalanine intake is normally metabolized into tyrosine (Tyr), the
amino acid precursor to dopamine and norepinephrine (van Spronsen and Enns 2010).
PKU impairs the conversion of Phe to Tyr leading to an accumulation of Phe, which is
neurotoxic (Burgard et al. 2009). Many treatment centers recommend maintaining blood
Phe concentrations between 120 to 360 μmol/L for optimal outcomes.
Potential Consequences of PKU
Untreated PKU causes severe neurological damage, especially to developing
white matter. Symptoms may include profound mental retardation, microcephaly,
delayed speech, seizures and behavior abnormalities (Sharman et al. 2009). However,
even with early and continuous treatment, patients with PKU exhibit mild deficits in
executive and intellectual functioning, including processing speed, motor skills,
perception and visual spatial abilities, and language (Gassio et al. 2005; Janzen and
Nguyen 2010).
Executive Functioning Deficits
Executive functioning is characterized by the ability to plan and organize, use
working memory, control impulsivity, switch tasks, maintain sustained attention, and
integrate information across space and time (Williams et al. 2008; Sharman et al. 2009).
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Appropriate executive functioning is dependent on two areas of the prefrontal cortex in
the brain: the dorsolateral prefrontal cortex and the orbitomedial prefrontal cortex.
Insults to the dorsolateral region are related to cognitive impairments and those to the
orbitofrontal region result in behavioral disturbances (Antshel and Waisbren 2003).
Attention is one of the most prominent executive functioning skills. A welldeveloped executive system is required in order to initiate, sustain, and direct attention
(Antshel and Waisbren 2003). Similarities in brain function between attention deficit
hyperactivity disorder (ADHD) and PKU may contribute to the concentration difficulties
seen in PKU. Among 38 children with PKU, 50 percent of parents reported attention
deficit symptoms in their children and 26 percent used a stimulant medication for these
symptoms. Stimulant use was remarkably higher than that for the general population (5
percent) and compared to a control population with type 1 diabetes (6.5 percent), as this
population also has a chronic metabolic disease. ADHD is believed to be associated with
decreased levels of dopamine and norepinephrine and with executive functioning deficits
(Arnold et al. 2004). The onset of ADHD symptoms in PKU may be attributed to a gene
called MAO-B, which can increase concentrations of the toxic Phe metabolite
phenylethylamine (Feillet et al. 2010).
A case-control study (Leuzzi et al. 2004) demonstrated that PKU patients had
impaired performance on executive functions tests compared to age-matched controls.
PKU patients exhibited mild deficits in planning and sustained attention. Those with Phe
levels over 400 μmol/L (mean of median Phe levels from birth to 4 years and 6 months
before and after neuropsychological assessment) exhibited more pronounced impairment
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of selective attention, behavioral inhibition, working memory, and goal-directed
behavior.
Intelligence and Academic Achievement
Since the dietary treatment for PKU was established, researchers have explored
the quality of mental development in patients with PKU. Dobson et al. (1976) reported a
discrepancy in the IQ of PKU children and their family members. Later studies proposed
that intellectual function was related to dietary control, as children with good dietary
control had comparable IQs to their non-affected siblings in the first years of life. While
appropriate dietary control may result in normal intelligence, academic skills, specifically
language and arithmetic, may be impaired (Fishler et al. 1987; Moyle et al. 2007).
Azen et al. (1996), who followed 120 children with PKU, discovered higher
language scores in children that maintained better control of blood Phe concentrations
than children who discontinued or liberalized the diet (Azen et al. 1996; Williams et al.
2008). Brumm et al. (2004) reported a positive correlation between years on diet and
verbal fluency, expressive naming, and receptive vocabulary in 24 adults with PKU.
Those with Phe over 1000 μmol/L at the time of testing scored significantly lower on
these measures than those with Phe below 1000 μmol/L (Brumm et al. 2004). However,
multiple studies demonstrate a reduction in language scores over time for all groups with
PKU, despite the quality of treatment (Gassio et al. 2005; Moyle et al. 2007).
Deficits in perceptual and visual-spatial skills have also been recognized in
individuals with PKU. Children with PKU showed lower detection of visual contrast
than healthy controls after controlling for differences in IQ and visual acuity (p < 0.005)
(Diamond et al. 1996; Janzen and Nguyen 2010). Gassio et al. (2005) demonstrated a
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negative correlation between metabolic control during the first 6 years of life and visualspatial scores (r = -0.553, p = 0.008). Calculation and spelling skills are dependent upon
visual-spatial recognition, visual perception, and memory; therefore, mild deficits in
visual-perceptual skills may contribute to spelling and calculation difficulties common in
patients with PKU (Chang et al. 2000; Antshel 2010). Chang et al. (2000) reported out of
32 early treated patients, 19.4 percent scored below average in calculation skills. Another
study reported 33 percent of students with PKU had more difficulty with mathematics
and spelling than their peers (Weglage et al. 1993).
Gassio et al. (2005) demonstrated that patients with PKU receiving early and
continuous dietary treatment scored significantly lower in intelligence tests than their age
matched controls (p < 0.0001). While subjects were within the normal IQ range (102
9), they scored an average of 10 points lower than control subjects (112

8). Differences

in fine motor skills, attention problems, executive functions, and school problems were
statistically significant as well. There was no correlation between individuals with school
problems and dietary control for the first 6 years of life. However, those with school
problems had significantly higher concurrent index of dietary control (mean of median
Phe levels measured at 6-month intervals) during the last 6 months when compared to the
first 6 years of life. Patients exhibiting school problems also had lower intelligence
scores (98

8; p = 0.033) (Gassio et al. 2005).

Processing Speed
Antshel and Waisbren (2003) described processing-speed deficits in 46 children
with PKU using the Wechsler Intelligence Scale for Children (WISC)-III Coding subtest.
They showed reduced speed of information processing when compared to siblings. In
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addition, studies in adolescents with early-treated PKU demonstrated impaired
performance on neuropsychological tests compared with those with type 1 diabetes (p <
0.001). However, deficits were not due to specific cognitive abilities but were attributed
to slower processing speed, which was correlated with elevated blood Phe levels (Janzen
and Nguyen 2010).
Moyle et al. (2007) reported that slowed information processing is the dominant
feature in adults with PKU rather than impaired executive function, even for those
maintaining a Phe-restricted diet. A meta-analysis including 11 studies demonstrated
patients with PKU scored an average of one SD below controls on measures on
processing speed (Moyle et al. 2007). Magnetic resonance imaging (MRI) studies on 15
adults with PKU found those with an abnormal scan scored significantly lower of
measures of processing speed (p = 0.018 and 0.048) (Brumm et al. 2004). When
compared to a control group, early treated adults with PKU that were currently off diet
had significant differences in the Processing Speed Index (PSI) and the Perceptual
Organization Index (POI) of the Wechsler Adult Intelligence Scale-III (WAIS)-III. There
was no significant correlation between POI and PSI and lifetime Phe levels, which
supports the hypothesis that adults with PKU may have reduced processing speed
regardless if they continue the Phe-restricted diet (Moyle et al. 2007).
Weglage et al. (1999) indicated that there is decreased susceptibility to the
damaging effects of elevated Phe concentrations as patients with PKU become older.
Twenty adolescent patients with PKU and 20 controls were administered a test measuring
IQ twice at mean ages 11 and 14 years.

The initial test showed a significant negative

correlation between lifetime Phe levels and performance (r = -0.33, p < 0.05). Despite
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significantly elevated Phe concentrations during the second exam, the patient scores
improved 4-6 points from the first exam (Weglage et al. 1999). Brumm et al. (2004) also
reported cognitive deficits in adults were more highly correlated with treatment history
rather than current Phe levels. This does not encourage the removal of dietary treatment
during adolescence, but it suggests relaxation of diet may not result in progression of
neuropsychological deficits.
Pietz et al. (1997) suggested that adults with PKU may have an increased
prevalence of psychiatric disorders despite continuing dietary treatment. When
comparing 35 adults with PKU to a control group of 181 18-year-old subjects, 25.7
percent of those with PKU exhibited psychiatric disorders compared to 16.1 percent of
controls. The psychiatric symptoms included depressed mood, phobias, generalized
anxiety, hypochondria worries, and anxiety at work (Pietz et al. 1997). However, a study
comparing women who were late-treated or off-diet with early- and continuously-treated
women demonstrated significantly higher scores on measures of social introversion and
psychopathology than the early-treated group (Brumm and Grant 2010).

Late-Treated PKU
While brain damage from elevated Phe concentrations cannot be reversed, latediagnosed patients (mean age 2.44 years) may still benefit from dietary therapy (Trefz et
al. 2000). Koch et al. (1999) showed that out of 28 late but well treated patients, 18 were
able to live independently as adults without residential care. The initial measures of IQ
(52.7 ± 16.1) in a group of 40 late-treated patients positively correlated with final
measures of IQ in adulthood (79 ± 16.4) (p < 0.0001). The degree of brain damage may
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be reflected in the initial measures of IQ, thus gaining some predictive value for
estimating the IQ in adults.
Pathophysiology of Brain Dysfunction
The influence of neurotoxic agents or metabolites on the developing brain is
dependent on two factors: ability to access the nervous system and timing of exposure.
The brain is less vulnerable to environmental insults if it occurs before or after
development (Rice and Barone 2000). Different areas of the brain mature on distinctive
timelines during pre- and postnatal periods. Numerous studies corroborate that neuronal
development in humans continues from early embryogenesis throughout adolescence. In
addition, remodeling and change to the nervous system continues beyond adolescence
into adulthood in response to environmental and genetic stimuli (Rice and Barone 2000).
The development process of the central nervous system is comprised of a series of
chronological and parallel events. Disturbance of one event may impact later
development. The neurodevelopmental consequences of exposure to elevated Phe are
dependent on the timing and degree of the exposure. Therefore, the age at which
exposure occurs and the duration of the exposure contribute to the extent of brain
dysfunction in those with PKU (Antshel and Waisbren 2003).
There are several hypotheses explaining the etiology of brain damage and
impairment in intelligence and executive functioning skills in those with PKU. These
include impaired myelination, white matter lesions, and dopamine depletion in the
prefrontal cortex. Elevated Phe and low Tyr seen in PKU are believed to impair
myelination (Dyer 2000; Gassio et al. 2005; Anderson et al. 2007). Oligodendrocytes,
which are necessary for the assembly and maintenance of myelin, are sensitive to high
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Phe. The development of oligodendrocytes occurs after that of the neurons in a given
structure. The progression of myelination continues through adolescence, which
lengthens the period by which elevated Phe may be more detrimental (Rice and Barone
2000). If the myelination process is affected, the speed of the action potentials would be
decreased, causing slowed information processing (Moyle et al. 2007).
Reiss et al. (1996) used MRI scans to describe brain maturation in 85 healthy
children aged 5 to 17 years. Human brains reach adult weight by approximately 5 to 10
years of age. However, cortical grey matter and cerebral white matter volumes change
throughout childhood. The amount of cortical grey matter began to decrease in
participants as young as 5 years, suggesting the refinement of neuronal connections that
occurs naturally in healthy children. As cortical grey matter decreases, increased
myelination is thought to promote the synthesis of cerebral white matter. This expansion
of white matter was found mostly in the prefrontal cortex of the brain, which is known to
have substantial myelination during late childhood and early adulthood (Reiss et al.
1996).
Disturbed myelin synthesis and increased myelin turnover are proposed to be
involved in the etiology of white matter lesions (Anderson et al. 2007). The majority of
PKU patients, both early treated and untreated, display some degree of white matter
abnormality (Anderson et al. 2007; Williams et al. 2008). Dyer (1999) suggested
elevated Phe stalls myelination, resulting in severe hypomyelination if untreated.
Myelination is thought to progress normally in early treated patients. Therefore, white
matter abnormalities in this group are attributed to demyelination or dysmyelination of
previously formed myelin (Dyer 1999; Anderson and Leuzzi 2010).
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The initial pathological change in myelin associated with elevated Phe levels
involves splaying of the myelin lameliae within the sheath, increasing the water content.
The structural change and increased water content produce the typical MRI scan
appearance of abnormal white matter (Cleary et al. 1995). Anderson et al. found severity
of white matter abnormalities to be a significant predictor of executive functioning and
attention factors (RC = -0.40, p = 0.04) (Anderson et al. 2007). Feldmann et al. (2002)
demonstrated those with PKU had slower responses compared with non-PKU controls,
which was attributed to white matter abnormalities.
The degree of white matter abnormality detected by MRI scans was closely
associated with concurrent blood Phe concentrations. These abnormalities are partially
reversible with reduction of blood Phe levels. Cleary et al. (1995) showed a decrease in
the white matter change in 14 out of 41 patients with PKU. The decrease in severity
correlated both with the reduction in Phe between scans and the level of Phe attained, as
changes were only observed in those with Phe levels less than 900 μmol/L. The earliest
MRI changes were recognized after 2 months, likely related to myelin turnover times.
Neurotransmitters also play integral roles in brain development. It has been
hypothesized that certain critical periods of brain maturation require adequate exposure to
neurotransmitters (Pascucci et al. 2008). Neurotransmitters function differently during
development compared to adulthood. In adults, neurotransmitters mediate the
transmission across synapses. While this role is the same during development, they must
interact with receptors over a greater distance. Neurotransmitters are also required to
form a gradient necessary for pattern formation of numerous regions of the nervous
system and for differentiation of neurotransmitter systems (Rice and Barone 2000).
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Therefore, deficits in neurotransmitters during these critical periods caused by PKU may
impair brain maturation resulting in cognitive delay. Elevated plasma Phe concentrations
have been associated with lower levels of dopamine, norepinephrine, and serotonin
(Pascucci et al. 2008).
Pascucci et al. (2008) tested this hypothesis by measuring the availability of
neurotransmitters in mice with induced PKU. Healthy mice exhibited peak production of
neurotransmitters during the third week of life, which coincided with the critical period
for synapse formation and dendritic growth in the rodents’ cortices. Mice with PKU
demonstrated approximately 50 percent fewer neurotransmitters than healthy mice. The
results indicate age-dependent deficits in neurotransmitters during development in the
mouse model of PKU.
Dopamine depletion has been reported in early and continuously treated patients
with PKU (Anderson et al. 2007). Compared to other regions of the brain, the prefrontal
cortex is thought to be particularly sensitive to mild decreases in dopamine, as it has the
highest proportion of cerebral dopamine turnover. Patterns of activity in the prefrontal
cortex of the brain are responsible for executive function skills (Moyle et al. 2007). If
this area were impaired, one would only perceive isolated events without attention to
other details, which explains the potential for poor planning and organizational skills in
those with PKU. Brain motor tract functions are also dependent on dopamine (Arnold et
al. 2004). Gassio et al. (2005) reported a negative correlation with blood Phe levels and
motor function on the day of their study (r = -0.427, p = 0.033), which may indicate a
link between dopamine depletion and elevated Phe.
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Rice and Barone (2000) report that neurotoxic agents may cause a developmental
insult that is not clinically detected until much later in life, such as exposure to methyl
mercury or X-ray radiation. Developmental delays or transient delays could be masked
by temporary compensation from continued growth of the nervous system. Manifestation
occurs later in life when the body’s compensatory ability decreases with aging and the
brain undergoes loss of neurons and synaptic inputs (Rice and Barone 2000). The
potential for latent neurotoxicity has not been determined for patients with PKU (Frank et
al. 2007).
Dietary Therapy
In the 1950s, Horst Bickel developed the primary treatment for PKU involving a
Phe-restricted diet. It dramatically changed the prognosis of PKU patients. However, the
initiation of therapy must occur early in life, as dietary treatment will not reverse any
neurological damage that has occurred (Burgard et al. 2009). Strict adherence to a Pherestricted diet and supplemental medical formula prevents the debilitating consequences
of the disease. However, the treatment regimen is arduous, requiring regular collection of
blood samples, detailed food records, frequent appointments with a metabolic team, and
maintenance of a highly restrictive diet (Bilginsoy et al. 2005).
In infants, small amounts of Phe from breast milk and/or commercial infant
formulas are provided along with a Phe-free medical formula to meet calorie and protein
needs (Williams et al. 2008). In older children, dietary Phe intake must be calculated
based on the child’s plasma Phe concentration, age, growth rate, state of health, and
protein and calorie requirements (Acosta and Yannicelli 2001). Tolerance to Phe is
determined by gradually increasing prescribed phenylalanine and monitoring blood Phe
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concentrations (Burgard et al. 2009). Dietary Phe intake may be measured using mg Phe,
food equivalents (15mg Phe each), or grams of protein (1g of protein corresponding to
approximately 50 mg Phe). High protein foods such as eggs, meat, cheese, dried beans,
legumes, and milk must be avoided. Aspartame, a common artificial sweetener, should
also be avoided as Phe is cleaved from aspartic acid when metabolized (Williams et al.
2008).
Caloric intake should also be considered, as it plays a primary role in nitrogen
retention. Inadequate consumption of energy results in a negative nitrogen balance even
if protein intake is adequate. This is particularly concerning during illness due to loss of
appetite and subsequent catabolism, which releases Phe into the bloodstream (Przyrembel
and Bremer 2000). Calorie requirements are met using the prescribed protein intake,
medical formula, and foods free of phenylalanine.
As children and adolescents grow, their calorie and protein needs increase.
However, their prescribed Phe does not typically increase proportionally. Wendel et al.
(1990) analyzed the average protein and Phe intakes needed to maintain appropriate
plasma Phe in children from birth to six years of age. These children consumed an
average of 2.26 g protein per kg body weight at 6 months and 1.81 g/kg at 6 years. Mean
Phe intakes declined from 34 mg Phe/kg body weight at 6 months to 15mg/kg at 6 years.
The participants’ protein intake per kg body weight decreased by approximately 20
percent whereas Phe intake dropped approximately 56 percent (Wendel et al. 1990).
An individual’s protein needs are met with the use of a Phe-free elemental
formula in addition to natural protein. Phenylalanine-free amino acid modules typically
provide 80 to 85 percent of an individual’s daily protein requirements in addition to
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necessary macro- and micronutrients. However, the optimal dosage has yet to be
determined (MacDonald et al. 2006). It has been hypothesized that a higher amount of
protein substitute (2 g/kg/day) may lead to increased protein retention and compensate for
the potential for poor utilization of free amino acids. Free amino acids are absorbed and
oxidized faster than natural protein; therefore medical formula should be divided into
three doses per day to enhance utilization of amino acids (MacDonald et al. 2006; Olsson
et al. 2007). MacDonald et al. (2006) showed improved Phe control for those taking 2
g/kg/day of protein substitute compared to those taking 1.2 g/kg/day. However, these
results conflict with previous research.
A new alternative to free amino acid modules is glycomacropetide (GMP), which
is the first intact source of low-phenylalanine protein (van Calcar et al. 2009). GMP is a
64-amino acid glycophosphopeptide found in whey protein during cheese making. It is
produced when kappa-casein is metabolized into para-casein, which remains in the curd
and GMP in the whey. While pure GMP is free of phenylalanine, the Phe content of the
commercial form of GMP is 2.5 to 5.0 mg Phe per gram of protein (Ney et al. 2009).
GMP contains 2 to 3 fold greater amounts of the large neutral amino acids (LNAA)
isoleucine and threonine compared to other protein sources.
GMP foods may be designed to constitute one half of the required protein from
Phe-free medical formulas for those of school age or older (Ney et al. 2009). The results
of blind taste tests demonstrated a preference for GMP products over various amino acid
supplements in those with PKU (van Calcar et al. 2009). Potential benefits of GMP
include increased protein retention and improved use of amino acids for protein synthesis
by delaying the absorption of amino acids.

28
While a Phe-restricted diet with amino acid supplementation is indicated for those
with PKU, it does present potential risks. Patients with PKU undergoing dietary therapy
have an abnormal fatty acid profile and low levels of cholesterol and trace elements such
as iron, zinc, and retinol (Przyrembel and Bremer 2000; Williams et al. 2008). Patients
with PKU exclude the majority of animal products, which supply exogenous cholesterol,
fatty acids, and micronutrients (Przyrembel and Bremer 2000). However, it is unclear
whether these disturbances are due to inadequate intake or disordered biosynthesis of
these nutrients (Williams et al. 2008).
Research has established that maintenance of plasma Phe through a Phe-restricted
diet improves cognitive outcomes. There is also worldwide consensus that dietary
treatment should be initiated in infants with plasma Phe above 10 mg/dL. However,
clinicians in different countries and treatment centers within the US do not agree on the
optimal treatment range during different periods of life (Waisbren et al. 2007).
The United Kingdom (UK) advises infants and young children with PKU to keep
Phe levels between 120 to 360 μmol/L, with liberalization of plasma Phe control after
childhood. The German Working Group for Metabolic Diseases’ policy includes
maintenance of Phe levels between 42 to 240 μmol/L in those less than 10 years of age,
42 to 900 μmol/L between 10 and 15 years, and 42 to 120 μmol/L in those over 15 years.
The majority of US clinics use a treatment range of 120 to 360 μmol/L for those age 12
years and younger and 120 to 600 μmol/L for older patients (Waisbren et al. 2007).
Guidelines released by the Medical Research Council Working Party on PKU and
by a National Institutes of Health Consensus Panel stated that lifelong dietary treatment is
required for optimal outcomes in PKU (Wappner et al. 1999; NIH 2000). Increased
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cognitive and emotional dysfunction, behavior disorders, and neurological complications
have been identified in patients with PKU who discontinue dietary therapy (Gassio et al.
2005). In addition, patients who continue a Phe-restricted diet throughout life report
lower rates of asthma, mental disorders, hyperactivity and hypoactivity than those
discontinuing dietary treatment (Waisbren et al. 2007).
While clinicians support the slogan “Diet for Life,” it does not come without
challenges, such as obtaining social support, adhering to the prescribed diet, and the risk
of developing nutrient imbalances (Williams et al. 2008). Patient compliance to dietary
recommendations tends to decrease after early childhood (Weglage et al. 1992). Wendel
et al. (1990) reported a steady decrease in frequency of blood Phe level monitoring after 6
months of age. In addition to reduced blood Phe monitoring, there is a continual increase
in Phe concentrations as patients age. An observational study of Phe levels in 330
patients under 20 years of age reported 30 percent of blood Phe concentrations above the
recommended maximum value in children less than 4 years of age (Walter et al. 2002).
This number increased to 80 percent of levels in adolescents between 15 and 19 years.
The mean of median Phe levels for the participants less than 15 years gradually increased
with age but remained within the recommended concentrations. However, those aged 15
to 19 years had a mean median Phe above the treatment range.
Sapropterin Therapy
An alternative to using a Phe-restricted diet as the sole therapy for PKU is the use
of sapropterin dihydrochloride, the pharmacological equivalent of BH4. A randomized,
double-blind, placebo-controlled clinical trial on the efficacy of sapropterin
dihydrochloride treatment demonstrated decreased blood Phe concentrations in patients
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with PKU (Trefz et al. 2009). Only a portion (approximately 50 percent in mild PKU and
<10 percent in classic PKU) of patients responded to the treatment, as some lack
adequate amounts of residual enzyme activity required for this therapy to be effective
(Blau et al. 2009). In order to be determined responsive to sapropterin therapy, blood Phe
must decrease at least 30 percent from baseline levels. Treatment with this medication
often allows patients to increase their intake of natural protein sources, which could
improve nutritional balance. Sapropterin has been shown to be safe in patients 4 years
and older at doses up to 20 mg/kg/day (Trefz et al. 2009).
Enzyme Replacement Therapy
Those patients that do not respond to BH4 therapy may benefit from enzyme
replacement therapy, which is not dependent on residual PAH activity. A therapy under
investigation involves the substitution of PAH with pegylated phenylalanine ammonia-lyase
(PEG-PAL) (enzyme substitution therapy), which has shown some benefit in mouse models.
Biomarin Pharmaceutical Inc. is currently facilitating clinical trials using PEG-PAL to treat
patients with PKU who are unresponsive to BH4 therapy (Williams et al. 2008).
Treatment with Large Neutral Amino Acids
Large neutral amino acids (LNAAs) (phenylalanine, tyrosine, tryptophan,
threonine, isoleucine, leucine, valine, methionine, arginine, lysine, and histidine) share
the same cationic transporter protein to cross the blood brain barrier (Matalon et al. 2007;
Schindeler et al. 2007). These amino acids compete for access to the same transporter
protein and are driven by a concentration gradient. It is postulated that supplementation
with large doses of LNAAs with the exception of phenylalanine would reduce the entry
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of phenylalanine into the brain (Matalon et al. 2007). Schindeler et al. (2007)
demonstrated a modest decrease in plasma Phe in patients with PKU not taking medical
formula but no effect in those taking medical formula. This suggests LNAA therapy may
be most beneficial for those unable to comply with dietary restrictions.
CONCLUSION
While early treatment with a Phe-restricted diet prevents the most profound
consequences of PKU, it may not avert mild deficits in executive and intellectual
functioning. These impairments impact attention span, processing speed, visual-spatial
abilities, and language (Janzen and Nguyen 2010). Patients with PKU may exhibit
symptoms similar to ADHD, work less efficiently, have difficulty understanding charts
and diagrams, and have problems with articulation or comprehension of oral and written
materials. In addition, impaired executive abilities may inhibit use of executive strategies
to enhance learning and memory (Janzen and Nguyen 2010). The precise
pathophysiology of deficits in PKU has not been determined, but there are several
theories including impaired myelination, white matter abnormalities, and dopamine
depletion. White matter abnormalities in patients with PKU detected through MRI scans
are partially reversible by decreasing blood Phe to an acceptable range (Cleary et al.
1995).
It has been established that optimal metabolic control during the neonatal period
and early childhood is positively associated with intelligence (Brumm and Grant 2010).
Patient adherence to diet recommendations decreases after this period (Weglage et al.
1992). This is concerning, as brain development continues from early embryogenesis
throughout adolescence. Elevated Phe may be detrimental even in adulthood, which
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explains clinical recommendations for lifelong dietary therapy (Wappner et al 1999; NIH
2000).
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CHAPTER 3
CORRELATION OF AGE-SPECIFIC PHENYLALANINE LEVELS ON
INTELLECTUAL OUTCOME IN PATIENTS WITH PHENYLKETONURIA
ABSTRACT
It is widely appreciated by the medical community that subtle deficits in intellect,
academic skills and executive functioning exist in early treated phenylketonuria (PKU).
In this study, we described the relationship between intellectual outcome and
concentration/variation in blood phenylalanine (Phe) during specific developmental
periods (0-5 years, 6-10 years, >10 years). We also examined the association between
mean number of blood Phe samples and maintenance of Phe within treatment range (120360 μmol/L) and within one standard deviation (SD) of index of dietary control, defined
as the mean of 12-month median Phe. Retrospective data was collected from 55 patients
receiving treatment at the University of Utah Metabolic Clinic. Index of dietary control
(IDC) and SD blood Phe steadily increased and mean number of samples decreased
during each developmental period. The correlation between IDC during 6-10 years of
life and perceptual reasoning was -.370 (p = 0.006). Using multivariate linear regression,
IDC during 0-5 years and 6-10 years were associated with a 0.5-point decrease and 0.3point decrease in perceptual reasoning scores for every 100 μmol/L increase in blood
Phe, though associations were nonsignificant (p = 0.067; 0.082). SD of Phe was not
associated with any measure of intelligence. The likelihood of IDC >360 μmol/L in
those 6-10 years was 32.3% lower for each additional blood Phe sample per year (p =
0.001). The present study suggests frequent blood Phe monitoring during ages 6-10 years
may reduce blood Phe and prevent deficits in perceptual reasoning later in life.
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INTRODUCTION
Phenylketonuria (PKU; OMIM 262600) is an autosomal recessive disorder
characterized by impaired phenylalanine (Phe) metabolism due to a deficiency of
phenylalanine hydroxylase (PAH; EC 1.14.16.1) or defective synthesis/recycling of its
cofactor tetrahydrobiopterin. PKU impairs the conversion of Phe to tyrosine (Tyr),
resulting in a neurotoxic accumulation of Phe and a deficiency of Tyr (Waisbren et al.
2007; Burgard et al. 2009). Consequently, profound mental retardation ensues if
untreated. Treatment is initiated in the newborn period, which consists of a protein- or
Phe-restricted diet supplemented with Phe-free amino acid modules and frequent
monitoring of blood Phe levels (Waisbren et al. 2007). Recommended treatment range
for blood Phe is between 120 and 360 μmol/L. Lifelong continuation of dietary therapy
is recommended for optimal outcomes (Wappner et al. 1999; NIH 2000).
The neurodevelopmental consequences of elevated Phe are dependent on the
timing and degree of the exposure. Therefore, the age of occurrence and the duration of
the exposure contribute to the extent of brain dysfunction in those with PKU (Antshel and
Waisbren 2003). Different areas of the brain mature on distinctive timelines during preand postnatal periods. Numerous studies confirm that neuronal development in humans
continues from early embryogenesis throughout adolescence (Rice and Barone 2000).
The precise pathophysiology of PKU remains under investigation, but hypotheses include
impaired myelination, white matter lesions, and dopamine depletion in the prefrontal
cortex (Dyer 2000; Feldmann et al. 2002; Gassio et al. 2005; Anderson et al. 2007;
Anderson and Leuzzi 2010; White et al. 2010).
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While the most deleterious effects of PKU can be prevented with early and
continuous treatment, multiple studies corroborate the presence of subtle deficits in
intelligence, academic achievement, and executive functioning in early treated patients
(Stemerdink et al. 2000). These patients typically achieve average intelligence, but score
lower than the general population (Fishler et al. 1987; Gassio et al. 2005; Moyle et al.
2007; Gentile et al. 2010; White et al. 2010). Deficits specifically affect language skills,
visual-spatial abilities, and processing speed, which may present with difficulties in
reading, mathematics, spelling and slowed auditory comprehension (Chang et al. 2000;
Brumm et al. 2004; Gassio et al. 2005; Feillet et al. 2010; Janzen and Nguyen 2010).
A meta-analysis (Waisbren et al. 2007) documented a proportional correlation
between blood Phe during ages 0 to 12 years and 0 to 18 years with intelligence quotient
(IQ). Early treated patients with PKU were predicted to have a 1.3 to 3.9 point decrease
in IQ for every 100 μmol/L increase in blood Phe (calculated as mean Phe through both
12 and 18 years). In addition, each 100 μmol/L increase in concurrent Phe was predictive
of a 0.5 to 1.4 point decrease in IQ. A review of other longitudinal studies reported an
approximate 7-point decrease in IQ for each 300 μmol/L increase in blood Phe for those
less than 10 years of age (Burgard 2000). Studies by Anastasoaie et al. (2008) and
Vilaseca et al. (2010) also suggest variability of blood Phe as a useful predictor of
intelligence in PKU.
Patient compliance to dietary therapy tends to decrease after early childhood
(Weglage et al. 1992; Channon et al. 2005). Several collaborative PKU studies
demonstrated a continual increase in mean Phe levels in those older than 4 years of age in
relation to liberalization of diet restrictions and decreased frequency of blood Phe
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monitoring (Smith and Beasley 1989; Wendel et al. 1990; Azen et al. 1996; Burgard et al.
1997). Among an observational study of 330 patients under 20 years of age, 30% of
blood Phe levels were above the maximum recommended value in those less than 4
years, 50% in those 5 to 10 years, and 80% in those 15 to 19 years of age (Walter et al.
2002). This study also reported 80% of those from 0-4 years and 5-9 years adhered to the
recommended frequency of blood Phe testing compared to <75% of those aged 10-14
years and <50% in those 15-19 years.
The aim of the present study was to examine the relationship between index of
dietary control (mean of 12-month median Phe) and mean standard deviation (SD) of
blood Phe levels during specific developmental periods (0-5 years, 6-10 years, >10 years)
and most recent measures of intelligence in patients with PKU. Frequency of blood Phe
monitoring during each developmental period was also assessed to determine the
likelihood of achieving index of dietary control (IDC) within treatment range and mean
SD of blood Phe within one SD of IDC.
METHODS
Subjects
The University of Utah Metabolic Clinic, Salt Lake City, UT, treats
approximately 175 patients with PKU that reside in Utah, Idaho, and Wyoming.
Retrospective data was collected from 55 patients that met the following inclusion
criteria: (1) dietary treatment initiated within the first 2 months of life, (2) continuous
treatment, (3) age above 5 years, (4) at least one neuropsychological evaluation, (5) no
maternal PKU (brain damage in utero caused by elevated maternal plasma Phe) or
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cognitive dysfunction from unrelated causes. This study was reviewed and approved by
the Institutional Review Board at the University of Utah.
Biochemical Methods
Routine measurements of blood Phe concentrations were collected using the
Guthrie technique and fluorometric Phe measurement until the year 2006, after which
they have been analyzed by tandem mass spectrometry.

Quantitative plasma amino

acids were collected during appointments at the University of Utah Metabolic Clinic and
were analyzed by ion-exchange chromatography. The two different methods used to
analyze Phe concentrations were comparable according to a study by Gregory et al.
(2007) and also by an internal study performed at Associated Regional and University
Pathologists (ARUP) laboratories that conduct newborn screening and plasma amino acid
analysis for the state of Utah.
Quality of metabolic control each developmental period was calculated as the
mean of median blood Phe levels in 12-month intervals, referred to as the index of dietary
control. Mean SD blood Phe levels were also computed in 12-month intervals. The
median blood Phe was chosen over the mean blood Phe, as the median corrects for
fluctuations in blood Phe due to illness (Vilaseca et al. 2010). Lifetime data consisted of
the mean of all median and SD Phe levels throughout the patients’ life. Only Phe levels
acquired prior to the most recent measure of IQ were included in statistical analyses. Due
to the known effect of concurrent Phe concentration on cognitive testing performance,
Phe concentrations within 10 days of cognitive testing were assessed (de Sonneville et al.
2010). Diagnostic Phe, defined as highest pretreatment blood Phe concentration, was
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used to classify severity of PKU phenotype with levels >1200 μmol/L as classic, 6001200 μmol/L as moderate, and 120-600 μmol/L as mild PKU (Waisbren et al. 2007).
Frequency of blood Phe monitoring was examined for each developmental period
by taking the mean of the total number of samples in 12-month intervals for each
developmental period and lifetime. The University of Utah Metabolic Clinic has no
specific protocols regarding recommended frequency of Phe levels, though patients are
typically advised to take more frequent levels during infancy and early childhood.
Monthly levels are the minimum interval recommended for all patients. The advised
therapeutic range is between 120 and 360 μmol/L.
Neuropsychological Assessment
Measures of IQ, including verbal comprehension, perceptual reasoning, and
processing speed, were measured using the third and fourth editions of the Wechsler
Intelligence Scale for Children (WISC-III and WISC-IV) and the Wechsler Adult
Intelligence Scale (WAIS-III). The standard at the University of Utah Metabolic Clinic is
to complete cognitive testing on patients with PKU at ages 6, 12, and 18 years.
Due to structural differences in the WISC-IV compared to the WISC-III and the
WAIS-III, certain indexes/subtests were excluded from analysis, including Full Scale IQ
(Williams et al. 2003; Flanagan and Kaufman 2009). Subtests used for statistical analysis
included Block Design, Symbol Search, and Verbal IQ (VIQ) or Verbal Comprehension
Index (VCI). The normative sample range of the Block Design and Symbol Search
subtests are a mean of 10 with a SD of 3. The VCI mean standard score is 100 with an
SD of 15.
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The Block Design subtest was used to determine perceptual reasoning abilities. It
measures visual spatial reasoning and visual-constructional ability by requiring the
examinee to replicate a set of printed two-dimensional geometric patterns using blocks
within a specified time period (Wechsler 2003). The Symbol Search subtest involves an
individual scanning a group to determine if the target symbol is present, which
specifically examines mental processing speed and accuracy (Wechsler 2003; Flanagan
and Kaufman 2009).
Subtests measuring perceptual reasoning and processing speed are consistent
across the three tests; however, the composition of Verbal Comprehension Indexes vary.
The WISC-III contains Information, Similarities, Vocabulary, and Comprehension
subtests. The WISC-IV contains all but the Information subtest, whereas the WAIS-III
contains all but the Comprehension subtest. The Comprehension Subtest measures social
knowledge and awareness; therefore, it quantifies understanding of cause and effect,
knowledge of conventional standards of behavior, common sense, acquired knowledge,
verbal comprehension, and social judgment. The Information Subtest measures general
knowledge, including verbal comprehension and expression, acquired knowledge, longterm memory, US cultural knowledge, academic abilities, and auditory perception of
complex verbal information (Kaufman and Lichtenberger 1999; Wechsler 2003). Despite
the differences in VCI subtests between the third and fourth editions of the WISC, they
are highly correlated (r = 0.87) (Flanagan and Kaufman 2009).
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Statistical Analysis
Neuropsychological scores from the WISC-III, WISC-IV and the WAIS-III were
compiled for statistical analysis. Descriptive statistics were obtained for sample
characteristics and data related to blood Phe and cognitive testing. Pearson product
moment correlations were computed to assess the degree of association between most
recent measures of intelligence and treatment variables, which included diagnostic Phe
level, days of life at which dietary therapy was initiated, concurrent Phe within 10 days of
testing, IDC and mean SD Phe levels during each developmental period (0-5 years, 6-10
years, >10 years, and lifetime).
Treatment variables in the selected developmental periods were compared using
paired t-tests. The age of participants included in the sample varied from 6 to 33 years of
age, with approximately 34% of participants less than 10 years of age. If the >10 year
age group was further stratified, the number of samples in older age groups would not be
sufficient for statistical analysis. In addition, Vilaseca et al. (2010) reported no
significant difference in mean and SD blood Phe between 12-18 years and >18 years.
The specified age groups were also comparable to a similar study by Anastasoaie et al.
(2008).
Multivariable linear regression analysis was used to investigate a possible
association between measures of intelligence and IDC and mean SD Phe levels during
each developmental period. Covariates were added to the regression model stepwise to
determine which combination of independent variables created the best predictive model.
Parameters that were significantly related to cognitive outcomes in a bivariate regression
analysis were included in the multivariate regression model.
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Multivariable logistic regression analysis was used to examine the association
between mean number of Phe samples during each developmental period and IDC and
mean SD Phe for each age group. Age was included as a covariate in the analysis. All
statistical analyses were performed using SPSS version 18 for Windows software. A
two-sided P-value of < 0.05 was considered significant.
RESULTS
Descriptive statistics obtained for demographic data and treatment variables of the
sample are shown in Tables 3-1 and 3-2. Based on the diagnostic Phe level, 66.7% of
participants were classified as having classic PKU, 18.5% with moderate PKU, and
14.8% with mild PKU. The mean age at most recent measure of IQ was 11.04 years.
Average test scores were well within the normative sample range, which is consistent
with previous research (Leuzzi et al. 2004; Gassio et al. 2005; VanZutphen et al. 2007;
Gentile et al. 2010). In the current sample, 21.8% of participants scored below average
on the VCI, 14.5% on the Block Design subtest, and 23.5% on the Symbol Search
subtest. Analyses included a total of 7484 blood Phe samples from all participants.
Paired t-tests were used to compare the IDC and mean SD between developmental
groups. The IDC and mean SD Phe between all developmental groups were different
from each other (p < 0.05 for all). Differences between developmental groups 0-5 and 610 or >10 years were most significant (p = <0.001). There was no difference in the SD
blood Phe between 0-5 years and >10 years (p = 0.932). Mean number of blood Phe
samples between age groups 0-5 years and 6-10 years were significantly different (p =
0.000), but the number of samples between those 6-10 years and >10 years were
relatively stable (p = 0.997). As noted in Table 3-1, IDC and mean SD blood Phe levels
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steadily increased while mean number of Phe samples decreased during each age group.
Change in Phe levels from birth to 19 years is shown in Figure 3-1.

Table 3-1 Description of sample demographic and treatment variables
Variables

N

Mean

SD

Min

Max

Age at most recent measure of intelligence (years)
55
11.04
4.59
6
22
Diagnostic Phe (μmol/L)
54
1698
829
361
3789
Initiation of diet therapy (days of life)
51
14.27
6.74
5
30
a
Index of Dietary Control (μmol/L)
Lifetime
55
417
165
167
907
Age 0-5 years
55
361
127
155
817
Age 6-10 years
54
442
196
100
982
Age >10 years
31
595
258
165
1174
Concurrent Phe (within 10 days of cognitive testing)
37
631
374
42
1774
b
Mean number of blood Phe samples
Lifetime
55
10.9
4.1
3.95
23.7
Age 0-5 years
55
16.5
8.3
5.75
62
Age 6-10 years
54
7.4
3.6
1.8
16
Age >10 years
31
6.9
3.9
2
21
Most recent measure of intelligence (WISC/WAIS)c
Verbal Comprehension Index
55
99.2
13.6
69
132
Block Design Subtest
55
9.3
2.6
4
16
Symbol Search Subtest
51
9.3
2.9
1
14
Phe, phenylalanine; SD, standard deviation; WISC, Wechsler Intelligence Scale for Children; WAIS,
Wechsler Adult Intelligence Scale
a
Index of Dietary Control defined as mean 12-month median for each patient during the specified time
frame
b
Mean number of Phe samples defined as mean of total Phe samples in 12-month intervals during
specified ages
c
Most recent measures intelligence defined as the mean compiled scores of one of three cognitive tests for
each patient: WISC-III, WISC-IV, or WAIS-III
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Table 3-2 Distribution of demographic and treatment variables
Variables

N

%

Sex
Male
27
49
Female
28
51
a
Classification of PKU severity based on diagnostic level
Classic (>1200 μmol/L)
36 66.7
Moderate (600-1200 μmol/L)
10 18.5
Mild (120-600 μmol/L)
8 14.8
b
Index of Dietary Control within treatment range (120-360 μmol/L)
Age 0-5 years
34 61.8
Age 6-10 years
22 40.7
Age >10 years
6 19.4
Most recent measure of intelligence (WISC/WAIS)
Verbal Comprehension Index – below average scores c
12 21.8
d
Block Design Subtest – below average scores
8 14.5
Symbol Search Subtest – below average scores d
12 23.5
PKU, phenylketonuria; Phe, phenylalanine; WISC, Wechsler Intelligence Scale for Children; WAIS,
Wechsler Adult Intelligence Scale
a
Diagnostic level defined as highest Phe level prior to initiation of dietary therapy
b
Index of Dietary Control defined as mean 12-month median Phe level for each patient during the
specified age group
c
Classified as performing 1 standard deviation below the normative sample on the WISC-III, WISC-IV,
or WAIS-III for each patient (scoring <85), d (scoring <7)

Figure 3-1 Index of Dietary Control, defined as the mean 12-month median of Phe
levels, for all patients per year of life (raw data). Therapeutic Range (120-360 µmol/L)
defined as the recommended concentration of blood Phe to prevent neurologic decline.
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Diagnostic Phe, days of life at which diet therapy was initiated, concurrent Phe,
and mean SD Phe during all age groups were not associated with any measure of
intelligence using Pearson product moment correlations (Table 3-3). Perceptual
reasoning was significantly correlated with IDC during 0-5 years, 6-10 years, and lifetime
but not >10 years. Analysis of variance (ANOVA) revealed a significant difference in
mean perceptual reasoning scores among those with Phe greater than treatment range
(>360 μmol/L) at the time of testing (within 10 days) compared to those within treatment
range (p = 0.020).

Table 3-3 Pearson product moment correlations between neuropsychological tests and
treatment variables
Variables

Verbal
Comprehension c

Perceptual
Reasoning d

Processing
Speed e

Diagnostic Phe
.001 (.997)
-.003 (.983)
-.219 (.126)
Initiation of diet therapy (days of life)
-.122 (.395)
-.156 (.275)
-.072 (.631)
a
Index of Dietary Control
-.128 (.352)
-.301 (.026)
-.108 (.451)
Lifetime
-.141
(.303)
-.280
(.038)
-.025 (.863)
Age 0-5 years
-.174 (.208)
-.370 (.006)
-.060 (.680)
Age 6-10 years
.058
(.756)
-.297
(.105)
.027 (.892)
Age >10 years
Concurrent Phe within 10 days of testing
-.025 (.885)
-.266 (.111)
-.205 (.246)
b
Mean SD of blood Phe
-.078 (.569)
-.089 (.517)
-.071 (.619)
Lifetime
-0.41
(.766)
.010
(.943)
-.060 (.674)
Age 0-5 years
-.111 (.426)
-.092 (.506)
-.092 (.527)
Age 6-10 years
.121
(.524)
-.224
(.233)
.016 (.936)
Age >10 years
Phe, phenylalanine; SD, standard deviation
a
Index of Dietary Control defined as mean 12-month median Phe levels for each patient during the
specified time frame
b
Mean standard deviation of blood Phe defined as mean 12-month SD for each patient during the specified
age group
c
Verbal comprehension derived from mean compiled scores of the Verbal Comprehension Index in one of
three cognitive tests: WISC-III, WISC-IV, or WAIS-III for each patient
d
Perceptual reasoning derived from mean compiled scores of the Block Design subtest in one of three
cognitive tests: WISC-III, WISC-IV, or WAIS-III for each patient
e
Processing speed derived from mean compiled scores of the Symbol Search subtest in one of three
cognitive tests: WISC-III, WISC-IV, or WAIS-III for each patient
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Bivariate regression analysis revealed no appreciable association between IDC
during all developmental periods including lifetime and verbal comprehension scores
(Figure 3-2). Interestingly, when WAIS-III scores were removed from the regression
analysis leaving only the Wechsler Intelligence Scale for Children, IDC during 0-5 years,
6-10 years, and lifetime significantly predicted verbal comprehension scores
(Figure 3-3).

Figure 3-2 Bivariate regression analysis: association between Verbal Comprehension
Index (VCI) scores and Index of Dietary Control, defined as the mean 12-month median
of Phe levels for each patient during the specified time frame. VCI scores were compiled
from three different neuropsychological tests (Wechsler Intelligence Scale for Children
III and IV and Wechsler Adult Intelligence Scale III). P values < 0.05 were considered
significant.
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Figure 3-3 Bivariate regression analysis: association between Verbal Comprehension
Index (VCI) scores (excluding the Wechsler Adult Intelligence Scale scores) and Index of
Dietary Control, defined as the mean 12-month median of Phe levels for each patient
during the specified time frame. VCI scores were compiled from two different
neuropsychological tests (Wechsler Intelligence Scale for Children III and IV). P values
< 0.05 were considered significant.

Bivariate regression analysis of IDC during 0-5 years, 6-10 years, and lifetime
significantly predicted the variance in perceptual reasoning scores (Figure 3-4). A
multivariate regression model including IDC and mean number of Phe samples for the 610 year age group accounted for 16.3% of variance in perceptual reasoning scores
(F(2,51) = 4.981, p = 0.011). The IDC regression coefficient for 6-10 years was
nonsignificant after controlling for number of blood Phe samples (p = 0.082). The model
including mean SD of blood Phe (6-10 years) and number of samples accounted for
11.5% of the variance in Block Design scores (F(2,51) = 3.316, p = 0.044). However, the
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significance was attributed to frequency of sampling (p = 0.017) rather than mean SD of
blood Phe (p = 0.667).

Figure 3-4 Bivariate regression analysis: association between Block Design Subtest
scores measuring perceptual reasoning skills and Index of Dietary Control, defined as the
mean 12-month median of Phe levels for each patient during the specified time frame.
Block Design scores were compiled from three different neuropsychological tests
(Wechsler Intelligence Scale for Children III and IV and Wechsler Adult Intelligence
Scale III). P values < 0.05 were considered significant.

Multivariate linear regression (Table 3-4) determined that every 100 μmol/L
increase in IDC measured throughout the lifespan was associated with a 0.4-point
decrease in perceptual reasoning scores (p = 0.111). IDC from 0-5 years was associated
with a 0.5-point decrease in Block Design scores for every 100 μmol/L increase in blood
Phe (p = 0.067), though data was nonsignificant. Processing speed, measured with the
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Symbol Search subtest, was not associated with IDC or mean SD Phe for any age group
using bivariate and multivariate regression models (Figure 3-5).

Figure 3-5 Bivariate regression analysis: association between Symbol Search Subtest
scores measuring processing speed and Index of Dietary Control, defined as the mean 12month median of Phe levels for each patient during the specified time frame. Symbol
Search scores were compiled from three different neuropsychological tests (Wechsler
Intelligence Scale for Children III and IV and Wechsler Adult Intelligence Scale III). P
values < 0.05 were considered significant.

While there was no significant correlation between diagnostic Phe and IDC or
cognitive scores, diagnostic Phe had a significant positive correlation with the variation
of Phe levels during ages 0-5 years (r = 0.547, p = 0.000), 6-10 years (r = 0.475, p =
<0.001), and lifetime (r = 0.537, p = 0.000). The IDC for all developmental periods were
significantly correlated to SD blood Phe levels (p < 0.01 for all).
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Table 3-4 Multivariate Regression: association between Index of Dietary Control and
mean standard deviation of Phe and measures of intelligence

Dependent Variables

Independent Variables % Variance

F

P

RC

P

Verbal Comprehension
IDC Lifetime
IDC 0-5 yrs
IDC 6-10 yrs
IDC >10 yrs
Mean SD Phe Lifetime
Mean SD 0-5 yrs
Mean SD 6-10 yrs
Mean SD >10 yrs

6.4
.7.1
9.1
1.0
6.7
7.0
9.7
5.2

1.769
1.998
2.548
.141
1.855
1.962
2.732
.739

.181
.146
.088
.869
.167
.151
.075
.487

-.003
-.011
-.001
.002
-.014
-.019
-.017
.027

.799
.455
.897
.830
.636
.482
.556
.441

IDC Lifetime
IDC 0-5 yrs
IDC 6-10 yrs
IDC >10 yrs
Mean SD Phe Lifetime
Mean SD 0-5 yrs
Mean SD 6-10 yrs
Mean SD >10 yrs

12.1
11.4
16.3
8.9
8.2
5.6
11.5
6.2

3.566
3.340
4.981
1.364
2.309
1.535
3.316
.890

.035
.043
.011
.272
.109
.225
.044
.422

-.004
-.005
-.003
-.002
-.003
-.002
-.002
-.006

.111
.067
.082
.125
.585
.770
.667
.214

Perceptual Reasoning

Processing Speed
IDC Lifetime
2.1
.522
.597
-.001
.633
IDC 0-5 yrs
0.1
.024
.977
-.001
.853
IDC 6-10 yrs
0.9
.220
.803
.000
.933
IDC >10 yrs
0.1
.010
.990
.000
.901
Mean SD Phe Lifetime
2.1
.524
.596
-.003
.630
Mean SD 0-5 yrs
0.4
.088
.916
-.003
.687
Mean SD 6-10 yrs
1.6
.392
.678
-.004
.558
Mean SD >10 yrs
0.9
.110
.896
.000
.648
Phe, phenylalanine; SD, standard deviation; IDC, index of dietary control; RC, regression coefficient;
p, significance
Covariates of the regression model include concurrent Phe (within 10 days of testing), SD blood Phe, mean
number of Phe samples.
a
IDC defined as mean 12-month median for each patient during the specified time frame
b
Mean standard deviation of blood Phe defined as mean 12-month SD for each patient during the specified
age group
c
Verbal comprehension derived from mean compiled scores of the Verbal Comprehension Index in one of
three cognitive tests: WISC-III, WISC-IV, or WAIS-III for each patient
d
Perceptual reasoning derived from mean compiled scores of the Block Design subtest in one of three
cognitive tests: WISC-III, WISC-IV, or WAIS-III for each patient
e
Processing speed derived from mean compiled scores of the Symbol Search subtest in one of three
cognitive tests: WISC-III, WISC-IV, or WAIS-III for each patient
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Lifetime mean number of blood Phe samples and samples from 6-10 years
significantly predicted the likelihood of maintaining blood Phe within the treatment range
of 120-360 μmol/L after controlling for age. Every additional blood Phe sample per year
of life predicted a 1.2 percent decreased risk of IDC above treatment range (p = 0.034),
and every additional sample per year from ages 6-10 years predicted a 32.3 percent
decreased risk of blood Phe over 360 μmol/L (p = 0.001). For every additional year of
life from birth to 5 years, participants had a 25 percent increased risk of IDC above
treatment range (p = 0.001). This risk was increased 14.6 percent from 6 to 10 years of
age (p = 0.039). Mean number of Phe samples did not significantly predict the
probability of mean SD blood Phe within one SD of the IDC per age group (Table 3-5).

Table 3-5 Logistic Regression: number of blood Phe samples predicting likelihood of
maintaining blood Phe within treatment range of (120-360 μmol/L) and stability of Phe
within one SD per age group
Number of Blood Phe Samples
a

Odds
Ratio
.988
.925
.677
.959

95% CI
Lower
.731
.817
.534
.766

95% CI
Upper
1.021
1.049
.859
1.201

Age
Odds
Ratio
1.462
1.250
1.146
1.248

95% CI
Lower
1.110
1.098
1.007
.995

95% CI
Upper
1.461
1.423
1.304
1.656

Phe per Age Group
P
P
Lifetime
.034
<.001
0-5 years
.225
.001
6-10 years
.001
.039
>10 years
.714
.054
Phe SD per Age Group
Lifetime b
.982 .188
.899
1.163 1.372
.013
1.093
1.382
0-5 years c
1.066 .166
.931
1.172 1.217
.052
1.061
1.430
d
6-10 years
.687 .136
.886
1.272 1.138
.148
1.048
1.294
>10 years e
1.078 .543
.746
1.124 1.199
.110
1.005
1.472
Phe, phenylalanine; SD, standard deviation; p, significance; CI, confidence interval
Age was included as a covariate in the regression model
a
Phe per age group defined as mean 12-month median for each patient during the specified time frame
1 SD defined as: Lifetime 165b; 0-5 years 127c; 6-10 years 196d; >10 years 258e
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DISCUSSION
The present study demonstrates an important link between blood Phe levels
during the 6-10 year developmental period and perceptual reasoning skills, specifically
visual-spatial reasoning and visual constructional ability measured by the Block Design
subtest. IDC had a significant negative correlation with Block Design scores though no
association was found with mean SD blood Phe. IDC and number of Phe samples
accounted for 16.3 percent of the variance in perceptual reasoning, but using multivariate
regression, IDC was nonsignificant after controlling for number of blood Phe samples.
Despite adequate treatment, patients with PKU demonstrate impairments that
worsen over time in arithmetic, reading comprehension, basic spelling, and perceptual
skill (Stemerdink et al. 2000). In a previous study, teachers reported that 33 percent of
students exhibited more problems in mathematics and spelling than other students
(Weglage et al. 1993). Berry et al. (1979) demonstrated those with early treated PKU
scored significantly lower on measures of mathematical skills compared to healthy
controls (p < 0.05). Visual-spatial and perceptual deficits negatively impact these skills,
which may be misinterpreted as lower intelligence (Chang et al. 2000; Channon et al.
2009; Antshel 2010; Janzen and Nguyen 2010). Data from the present study
demonstrates blood Phe levels >360 μmol/L within 10 days of cognitive testing in the 610 year age group produced significantly different results from those with blood Phe
<360 μmol/L. Therefore, maintaining IDC <360 μmol/L during ages 6-10 years may
reduce the risk of developing academic impairments related to perceptual reasoning.
The PKU Adult Collaborative Study (Brumm et al. 2004) revealed a negative
association between language functioning skills and lifetime blood Phe levels and a
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positive correlation with number of years on dietary therapy. Koch et al. (1999) also
reported higher language scores for those who continued a Phe-restricted diet beyond 12
years of age compared to those that discontinued diet therapy at 12 years. Additionally,
measures of verbal fluency, expressive naming, and receptive vocabulary were
significantly lower for those with concurrent Phe >1000 μmol/L compared to patients
with Phe <1000 μmol/L (Brumm et al. 2004). The present study found no significant
associations between treatment variables and verbal comprehension scores. Frequency of
blood Phe monitoring during the 6-10 age group predicted a 1.104-point increase in VCI
scores for every additional blood Phe sample per year, though data was nonsignificant
(p = 0.071).
Speed of processing measured by the Symbol Search subtest was not associated
with IDC or mean SD blood Phe during any developmental period. Brumm et al. (2004)
found no significant association between current Phe levels and processing speed in
adults as measured by the Trail-Making Test Part A. However, processing speed was
significantly correlated with abnormal MRI scans, which are associated with elevated
blood Phe (Solan 1987; Chang et al. 2000; Brumm et al. 2004; White et al. 2010). While
measures of processing speed were not sensitive to concentration or variability of blood
Phe in the present study, deficits are commonly featured in early and continuously treated
patients with PKU when compared to healthy controls (Cleary et al. 1995; Kaufman and
Lichtenberger 1999; Channon et al. 2005; Janzen and Nguyen 2010).
Lezak (1995) reported IQ tests are typically insensitive to subtle cognitive
deficits. The Block Design subtest appeared to be more sensitive to IDC and mean SD
blood Phe levels than the VCI or the Symbol Search subtest. Exclusion of scores from
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the WAIS-III altered results from analyses predicting VCI. After excluding the WAIS-III
scores from analysis, the IDC from 0-5 years significantly predicted a 5.1-point decrease
in VCI scores for every 100 μmol/L increase in blood Phe (p = 0.002). Analysis of
WAIS-III scores only was not possible due to small sample size. This suggests the
Comprehension subtest included in the WISC-III and -IV was more sensitive to blood
Phe levels than the Information subtest in the WAIS-III.
Classification of PKU severity based on diagnostic Phe was not related to IDC,
but it was significantly correlated to mean SD Phe levels. This suggests that the severity
of the PKU phenotype may not predict the likelihood of maintaining blood Phe within
treatment range (Moyle et al. 2007; Olsson et al. 2007), but may reflect an increased risk
of high variability in blood Phe (Moyle et al. 2007). In addition, IDC was positively
correlated with SD Phe, which is in agreement with previous studies suggesting higher
blood Phe concentrations lead to greater variability in Phe levels (Anastasoaie et al. 2008;
Vilaseca et al. 2010).
Frequency of blood Phe monitoring significantly predicted the likelihood of
maintaining IDC within treatment range between 6-10 years and throughout the lifespan.
Vilaseca et al. (2010) reported a significant difference (p = < 0.001) in IDC between
those with good (proportion of recommended samples was >90%), intermediate (>75%),
and poor (<75%) frequency of testing. It should be noted that recommended frequency
of testing is related to metabolic control. Patients with blood Phe levels consistently
above treatment range are recommended to take more frequent levels compared to
patients with good metabolic control. Mean number of samples per year of life were
below the minimum recommended frequency (monthly levels) in those 6-10 years, >10
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years, and lifetime. Therefore, appropriate recommendations for frequency of blood Phe
samples at different ages cannot be inferred from this data.
LIMITATIONS
There are several limitations that may impact the interpretation of results from the
present study. Participants in this study were not selected randomly but were chosen
from patients receiving treatment at the Utah Metabolic Clinic. Therefore, results may
not reflect the characteristics of the population. Intelligence was measured with selected
subtests of three different neuropsychological tests due to structural differences between
measures rather than full scale IQ. Eliminating subtests from statistical analysis may not
portray overall intelligence or compare to previous research measuring full scale IQ.
There is also an increased risk of type 1 error due to small sample size, large number of
exposure variables and multiple comparisons.
CONCLUSION
In summary, our findings suggest an association between the quality of metabolic
control during specific developmental periods and measures of intelligence. Appropriate
blood Phe control during ages 0-5 years and 6-10 years may have a greater influence on
perceptual reasoning abilities than other periods of life. The importance of regular
monitoring of blood Phe levels should be emphasized especially in those aged 6-10 years,
as increased blood Phe monitoring decreases the probability that IDC will exceed the
upper limit of the therapeutic range (360 μmol/L). Concentration and variability of blood
may impact specific areas of verbal comprehension abilities for those 0-5 years of age. It
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does not lend support to the hypothesis that variability in blood Phe may be a useful
indicator of intelligence later in life.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
It is widely accepted that metabolic control during early childhood is related to
intelligence later in life. The results from the present study support findings from
previous research in this regard. Quality of metabolic control had the most influence on
intelligence during the 0-5 year and 6-10 year developmental periods. Concentration and
variability in blood Phe in the 0-5 year age group significantly predicted verbal
comprehension skills in those less than 18 years, and concentration of blood Phe in the 05 year and 6-10 year age groups were related to perceptual reasoning abilities.
Perceptual reasoning was the most notably affected measure of intelligence. It
was significantly correlated to both mean of median Phe and concurrent Phe in the 6-10
year age group. It was also associated with the IDC Phe for lifetime levels and from 0-5
years. Impaired perceptual reasoning may negatively impact reading comprehension,
mathematics, and spelling (Chang et al. 2000). If perceptual reasoning abilities are
impaired as early as 6-10 years, these children may fall behind as they progress through
their schooling, which could reduce their long-term intelligence. Therefore, children with
PKU should regularly undergo cognitive assessment to identify potential learning
disabilities early in life in order to develop an appropriate education plan.
The relationship between Verbal Comprehension Index (VCI) scores and the
mean of median and standard deviation (SD) blood Phe in the 0-5 age group could
indicate that blood Phe impacts verbal comprehension during childhood, but the effect
dissipates as they become adults. It may also be related to the test itself, which measures
general knowledge as compared to social knowledge and awareness. Further research is
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needed to explore the impact of blood Phe during early childhood on long-term verbal
comprehension skills. Moreover, it would be of worth to prospectively compare
individual performance over-time, comparing the highest and the lowest score achieved
in VCI with Phe levels at different periods.
Mean number of blood Phe samples per year was significantly different from the
0-5 year age group to the 6-10 year age group. Middle to late childhood is often the age
where patients and their caretakers become more relaxed regarding diet restrictions and
blood Phe monitoring (Weglage et al. 1992). One possible rationale for this is due to the
previous guidelines to discontinue dietary therapy at 5 years of age. This gives the
impression that brain development is completed at this age and strict control of blood Phe
levels is no longer necessary. Therefore, families may be less likely to overcome
common barriers to compliance. Clinicians must reinforce the importance of regular
monitoring of blood Phe levels and appropriate dietary control for patients in the 6-10 age
group.
In a survey of 32 PKU patients and their primary caretakers residing in Utah, 78
percent reported utilizing blood Phe results to adjust dietary intake (Bilginsoy et al.
2005). The majority of caretakers agreed that blood Phe levels were their primary
indicator of how well they were doing. However, several participants also described
blood Phe testing as cumbersome and time consuming. A home blood Phe monitoring
device has been suggested to improve metabolic control in patients with PKU. Patients
universally reported that a home monitoring device would improve the management of
the disease and increase adherence to a Phe-restricted diet (Bilginsoy et al. 2005).

65
While the University of Utah Metabolic Clinic determines recommended
frequency of blood Phe monitoring on an individual basis, mean number of blood Phe
samples per year was less than the minimum recommended frequency for all age groups.
The impact of the number of blood Phe samples on VCI scores and IDC accentuates its
importance in the treatment of PKU. However, optimal frequency of testing cannot be
deduced from this data. Further guidance regarding this issue may emerge with the
development of a home blood Phe monitoring device.
Previous studies suggest variation in blood Phe may be a stronger indicator of
intelligence than blood Phe concentrations in those greater than 10 years (Anastasoaie et
al. 2008). The present study does not lend support to this hypothesis, but further research
is needed. If blood Phe variation is associated with later intelligence in PKU, the use of
medications, such as sapropterin dihydrochloride, may be useful to limit wide
fluctuations.
Determining predictors of long-term IQ in early treated patients with PKU is an
area of interest. Participants in a survey of early treated adults with PKU expressed
anxiety regarding uncertainty about their prognosis, as they are the first generation of
early-treated adults with PKU. This uncertainty pertained to length of life and how long
participants would retain their mental faculties in addition to the value of optimal blood
Phe levels (Frank et al. 2007).
The present study contributes to the debate regarding the impact of concentration
and variation of blood Phe during specific developmental periods on intelligence.
Overall, our findings suggest early detection and strict adherence to diet and blood Phe
monitoring would be beneficial to improve cognitive outcomes in patients with PKU.
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